Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1102 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1102-TPS1102 ◽

Cited By ~ 4

Author(s):

Jose Baselga ◽

Kenji Tamura ◽

Toshinari Yamashita ◽

Shanu Modi ◽

Eriko Tokunaga ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

P3-16-18: Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-p3-16-18 ◽

2011 ◽

Author(s):

JA O'Shaughnessy ◽

CRC Osborne ◽

MA Steinberg ◽

FA Holmes ◽

HS Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3288216 ◽

2018 ◽

Author(s):

Fei Ma ◽

Quchang Ouyang ◽

Binghe Xu ◽

Wei Li ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe

10.1158/1538-7445.sabcs14-ot3-1-10 ◽

2015 ◽

Author(s):

Kathy Miller ◽

Javier Cortes ◽

Sara A Hurvitz ◽

Ian E Krop ◽

Debu Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Open Label Trial

Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-p6-11-03 ◽

2017 ◽

Author(s):

IA Mayer ◽

CL Arteaga ◽

R Nanda ◽

KD Miller ◽

K Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Abstract OT3-1-08: The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-1-08 ◽

2013 ◽

Author(s):

IH Park ◽

KS Lee ◽

S-A Im ◽

KH Jung ◽

KH Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1

Annals of Oncology ◽

10.1093/annonc/mdw365.94 ◽

2016 ◽

Vol 27 ◽

pp. vi99

Author(s):

J. Cortes Castan ◽

S. Verma ◽

S. Hurvitz ◽

I.E. Krop ◽

D. Tripathy ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Previously Treated ◽

Open Label Trial

Abstract P5-15-04: The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

10.1158/1538-7445.sabcs16-p5-15-04 ◽

2017 ◽

Author(s):

IH Park ◽

S-A Im ◽

KH Jung ◽

JH Sohn ◽

YH Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-s5-7 ◽

2011 ◽

Cited By ~ 6

Author(s):

M Martin ◽

J Bonneterre ◽

CE Geyer ◽

Y Ito ◽

J Ro ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib*

10.1158/0008-5472.sabcs12-ot1-1-17 ◽

2012 ◽

Cited By ~ 2

Author(s):

T Hickish ◽

A Mehta ◽

M Jain ◽

C-S Huang ◽

N Kovalenko ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Open Label ◽

Open Label Study ◽

Label Study